FDA Approves Updates to Lilly's HumalogLabel

Eli Lilly and Company LLY today announced that the U.S. Food and Drug Administration approved the company's supplemental new drug application with the following updates to the Humalog label: continuous insulin infusion pump therapy in children 4 years of age and over with type 1 diabetes extension of the time-in-use in the external pump reservoir to a maximum of seven days; and extension of the time-in-use of the infusion set and of the infusion set subcutaneous insertion site to a maximum of three days.